Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish Group.
493 - 498
Enferm Infecc Microbiol Clin
MetadataShow full item record
INTRODUCTION: Limited data is available regarding the hepatic safety of maraviroc in patients co-infected with HIV and HCV and/or HBV. Our objective was to compare the hepatic safety profile and fibrosis progression in HIV-mono-infected patients and co-infected with HCV and/or HBV treated with maraviroc. METHODS: Retrospective multicentre cohort study of HIV-infected patients receiving treatment with a maraviroc-containing regimen in 27 hospitals in Spain. RESULTS: A total of 667 patients were analyzed, of whom 313 were co-infected with HCV (n=282), HBV (n=14), or both (n=17). Maraviroc main indications were salvage therapy (52%) and drug toxicity (20%). Grade 3-4 hypertransaminasaemia (AST/ALT >5 times ULN) per 100 patient-years of maraviroc exposure, was 5.84 (95% CI, 4.04-8.16) and 1.23 (95% CI, 0.56-2.33) in co-infected and HIV-mono-infected patients, respectively (incidence rate ratio, 4.77; 95% CI, 2.35-10.5). However, the degree of aminotransferase abnormalities remained stable throughout the study in both groups, and no significant between-group differences were seen in the cumulative proportion of patients showing an increase in AST/ALT levels greater than 3.5 times baseline levels. No between-group differences were seen in liver fibrosis over time. With a maraviroc median exposure of 20 months (IQR, 12-41), two patients (0.3%) discontinued maraviroc because of grade 4 hepatitis, and other 2 died due to complications associated to end-stage-liver disease. CONCLUSIONS: Maraviroc-containing regimens showed a low incidence of hepatitis in a large Spanish cohort of HIV-infected patients, including more than 300 patients co-infected with HCV and/or HBV. Co-infection did not influence the maximum liver enzyme level or the fibrosis progression throughout the study.
AuthorsCrespo, M; Navarro, J; Moreno, S; Sanz, J; Márquez, M; Zamora, J; Ocampo, A; Iribaren, JA; Rivero, A; Llibre, JM
Showing items related by title, author, creator and subject.
SCREENING FOR HEPATITIS C Response from Hepatitis C Trust, BASL, BIA, BVHG, BSG, and BHIVA to article asking whether widespread screening for hepatitis C is justified Foster, GR; Gore, C; Hudson, M; Moss, P; Ustianowski, A; Ryder, S; Bhagani, S (2015-02-24)
High levels of Hepatitis B surface antigen (HBsAg) can exclude significant fibrosis and distinguishes true 'immune-tolerance' in children and young adults with Chronic Hepatitis B Hansi, NK; Gill, US; Banerjee, A; Surendraraj, N; Patel, C; Naik, S; Foster, GR; Kennedy, PT (2014)
A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in hepatitis B e antigen-negative chronic hepatitis B. Lampertico, P; Messinger, D; Cornberg, M; Brunetto, M; Petersen, J; Kennedy, P; Asselah, T; Rothe, V; Caputo, A; Bakalos, G (Hellenic Society of Gastroenterology, 2018-07-26)Background: Peginterferon alfa-2a induces durable responses in some hepatitis B e antigen-negative patients, but robust pretreatment predictors are not available to identify likely responders. In this study we aimed to ...